Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 2:13 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 793–816 of 830 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Safety and Pharmacokinetics in Healthy Volunteer Subjects Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

First In Human, Single Escalating Oral Dose Study Of PF-06882961 In Healthy Adult Subjects

NCT03309241
View directory record Official record
Conditions
Healthy Subjects
Interventions
PF-06882961, Placebo
Drug · Other
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Apr 2, 2018 · Synced Oct 17, 2026, 2:13 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate Safety and Tolerability of Single Ascending Doses of Multiple Formulations of PF-06650833 in Healthy Subjects Under Fasted and Fed Conditions

NCT02224651
View directory record Official record
Conditions
Healthy
Interventions
PF-06650833, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 2, 2015 · Synced Oct 17, 2026, 2:13 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intravenous and Subcutaneous Single and Repeated Doses of SAR441344 in Healthy Adult Subjects

NCT05845996
View directory record Official record
Conditions
Healthy Volunteers
Interventions
SAR441344, placebo, Keyhole limpet hemocyanin
Drug · Biological
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 45 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Sep 16, 2025 · Synced Oct 17, 2026, 2:13 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

A Study to Assess Pharmacokinetics, Safety, and Tolerability of ABBV-903 in Healthy Japanese and Han Chinese Participants

NCT06009237
View directory record Official record
Conditions
Healthy Volunteers
Interventions
ABBV-903, Placebo for ABBV-903
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Anaheim, California
Source: ClinicalTrials.gov public record
Updated Nov 13, 2023 · Synced Oct 17, 2026, 2:13 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

AZD8683 Single Ascending Dose Study

NCT00979849
View directory record Official record
Conditions
Healthy Volunteers
Interventions
AZD8683, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 45 Years · Male only
Enrollment
130 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 2, 2010 · Synced Oct 17, 2026, 2:13 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Two-Part, Single Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of DS-7309 in Healthy Volunteers and Subjects With Type 2 Diabetes Mellitus

NCT01862939
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
DS-7309, placebo
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years to 45 Years
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated May 27, 2013 · Synced Oct 17, 2026, 2:13 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Caplacizumab Single and Multiple Dose Study in Healthy Japanese and White Subjects.

NCT03172208
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Caplacizumab Dose 1 iv (single-dose), Caplacizumab Dose 2 iv (single-dose), Caplacizumab Dose 2 sc (single-dose), Caplacizumab Dose 2 sc (multiple-dose), Placebo iv (single-dose), Placebo sc (single-dose), Placebo sc (multiple-dose)
Biological · Other
Lead sponsor
Ablynx, a Sanofi company
Industry
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Nov 14, 2017 · Synced Oct 17, 2026, 2:13 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Safety and Anti-leukemic Activity of Vodobatinib (K0706) for Treatment of Ph+ CML Resistant/Intolerant to ≥3 Prior CML Therapies

NCT02629692
View directory record Official record
Conditions
Healthy (For Part A), Chronic Myeloid Leukemia (for Part B and C)
Interventions
Vodobatinib (K0706) capsules
Drug
Lead sponsor
Sun Pharma Advanced Research Company Limited
Industry
Eligibility
18 Years and older
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2025
U.S. locations
8
States / cities
Downey, California • Los Angeles, California • Jacksonville, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced Oct 17, 2026, 2:13 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of AZD3366 in Healthy Subjects, Japanese and Chinese Subjects

NCT04588727
View directory record Official record
Conditions
Cardiovascular Disease
Interventions
AZD3366, Placebo, Ticagrelor, acetylsalicylic acid (ASA)
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
103 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Dec 18, 2023 · Synced Oct 17, 2026, 2:13 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Evaluate Pharmacokinetics (PK) and Safety of Oral Mobocertinib in Participants With Moderate or Severe Hepatic Impairment (HI) and Normal Hepatic Function

NCT04056468
View directory record Official record
Conditions
Hepatic Impairment, Healthy Volunteers
Interventions
Mobocertinib
Drug
Lead sponsor
Millennium Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 79 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
2
States / cities
Hialeah, Florida • Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Nov 3, 2023 · Synced Oct 17, 2026, 2:13 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

The Safety and Tolerability of STSA-1005 Following Intravenous Infusion in Healthy Subjects

NCT05085197
View directory record Official record
Conditions
Healthy
Interventions
STSA-1005 injection, Placebo
Drug
Lead sponsor
Staidson Biopharma Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Apr 18, 2022 · Synced Oct 17, 2026, 2:13 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A First-in-Human Study of CEE321 in Adult Subjects

NCT04612062
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
CEE321
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
2
States / cities
Glendale, California • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 28, 2022 · Synced Oct 17, 2026, 2:13 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacodynamics, Pharmacokinetics, Safety and Tolerability of Ultra Low Doses of Dapagliflozin in Healthy Subjects

NCT01135446
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
dapagliflozin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Oct 17, 2016 · Synced Oct 17, 2026, 2:13 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

An Investigational Study to Evaluate the Safety and Tolerability of Single and Multiple Ascending Doses of A-005

NCT07442149
View directory record Official record
Conditions
Healthy Volunteer
Interventions
A-005, Placebo
Drug
Lead sponsor
Alumis Inc
Industry
Eligibility
19 Years to 55 Years
Enrollment
135 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Mar 2, 2026 · Synced Oct 17, 2026, 2:13 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety Study of LY3041658 in Healthy Participants

NCT02148627
View directory record Official record
Conditions
Healthy
Interventions
LY3041658 (SC), LY3041658 (IV), Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2017
U.S. locations
2
States / cities
Glendale, California • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 15, 2017 · Synced Oct 17, 2026, 2:13 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Intrapulmonary Pharmacokinetics of Cefepime and Taniborbactam in Healthy Subjects

NCT04951505
View directory record Official record
Conditions
Healthy Subjects
Interventions
cefepime-taniborbactam
Drug
Lead sponsor
Venatorx Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Jun 8, 2025 · Synced Oct 17, 2026, 2:13 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

A 2-Part First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of CMTX-101

NCT05629741
View directory record Official record
Conditions
Community-acquired Pneumonia, Bacterial Pneumonia
Interventions
CMTX-101, Placebo
Drug
Lead sponsor
Clarametyx Biosciences, Inc.
Industry
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
8
States / cities
Augusta, Georgia • Idaho Falls, Idaho • Louisville, Kentucky + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 21, 2024 · Synced Oct 17, 2026, 2:13 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate How Aprocitentan is Safe and How it is Absorbed and Broken Down in the Body of Japanese and Caucasian Subjects

NCT03586570
View directory record Official record
Conditions
Healthy Subjects
Interventions
Aprocitentan 25mg, Placebo
Drug
Lead sponsor
Idorsia Pharmaceuticals Ltd.
Industry
Eligibility
20 Years to 45 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Anaheim, California
Source: ClinicalTrials.gov public record
Updated Nov 23, 2022 · Synced Oct 17, 2026, 2:13 PM EDT
Not listed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Safety and Tolerability of Single and Multiple Ascending Doses of HPN-01 in Healthy Subjects

NCT04481594
View directory record Official record
Conditions
Non-Alcoholic Steatohepatitis (NASH)
Interventions
HPN-01, Placebo
Drug
Lead sponsor
Hepanova Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Secaucus, New Jersey
Source: ClinicalTrials.gov public record
Updated Feb 10, 2021 · Synced Oct 17, 2026, 2:13 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety, Tolerability, and Pharmacokinetics Study of ATH-1020

NCT05169671
View directory record Official record
Conditions
Healthy Volunteers
Interventions
ATH-1020, Placebo
Drug
Lead sponsor
LeonaBio
Industry
Eligibility
18 Years to 85 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Newark, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 8, 2024 · Synced Oct 17, 2026, 2:13 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of TAK-510 in Healthy Adults

NCT04731922
View directory record Official record
Conditions
Healthy Participants
Interventions
TAK-510, TAK-510 Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 55 Years
Enrollment
124 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
2
States / cities
Las Vegas, Nevada • Austin, Texas
Source: ClinicalTrials.gov public record
Updated Mar 4, 2024 · Synced Oct 17, 2026, 2:13 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

AZD7268 Single Ascending Dose Study in Healthy Japanese Subjects

NCT00912353
View directory record Official record
Conditions
Healthy
Interventions
AZD7268, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
20 Years to 45 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Gelndale, California
Source: ClinicalTrials.gov public record
Updated Jan 29, 2013 · Synced Oct 17, 2026, 2:13 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

To Assess the Safety, Tolerability and Pharmacokinetics of AZD5634 Following Inhaled and Intravenous (IV)Dose Administration

NCT02679729
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
AZD5634 for inhalation, AZD5634 for infusion, Placebo
Drug · Other
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 50 Years
Enrollment
63 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
2
States / cities
Glendale, California • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 5, 2018 · Synced Oct 17, 2026, 2:13 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Single Ascending Dose Study of TD-1439 in Healthy Subjects

NCT02903095
View directory record Official record
Conditions
Healthy Subjects
Interventions
TD-1439, Placebo
Drug
Lead sponsor
Theravance Biopharma
Industry
Eligibility
19 Years to 55 Years
Enrollment
66 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Jan 19, 2021 · Synced Oct 17, 2026, 2:13 PM EDT